Theprubicin
Colon Cancer Liver Metastasis
Giammaria FiorentiniSmall moleculePhase 3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Colon Cancer Liver Metastasis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Raltitrexed Fudan University | Phase 4 | BB |
Ethiodized Oil Giammaria Fiorentini | Phase 3 | BB |
Inno-206 M.D. Anderson Cancer Center | Phase 2 | B |
(+)-VINCRISTINE Fujian Cancer Hospital | Phase 2 | B |
DEXTROSE Imunon | Phase 2 | CCC |
ASN007 Asana BioSciences | Phase 1 | CC |
Nkr-2 Cells Celyad Oncology SA | Phase 1 | CC |
Icosapent Ethyl University of Leeds | D |
Same molecule, other indications
Theprubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →